{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:57:50Z","timestamp":1783573070448,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ejpn.2008.10.006","type":"journal-article","created":{"date-parts":[[2008,12,3]],"date-time":"2008-12-03T18:58:23Z","timestamp":1228330703000},"page":"511-515","source":"Crossref","is-referenced-by-count":42,"title":["Safety of botulinum toxin type A in children younger than 2 years"],"prefix":"10.1016","volume":"13","author":[{"given":"Samuel Ignacio","family":"Pascual-Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Pascual-Castroviejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2008.10.006_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1469-8749.1995.tb12028.x","article-title":"Age and migration percentage as risk factors for progression in spastic hip disease","volume":"37","author":"Miller","year":"1995","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib2","first-page":"80","article-title":"[Use of botulinum toxin in the preventive and palliative treatment of the hips in children with infantile cerebral palsy]","volume":"37","author":"Pascual-Pascual","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1017\/S0012162201001086","article-title":"Hip dysplasia in bilateral cerebral palsy: incidence and natural history in children aged 18 months to 5 years","volume":"43","author":"Scrutton","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.apmr.2004.03.034","article-title":"Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A","volume":"86","author":"Pidcock","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ejpn.2008.10.006_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0012162206000557","article-title":"Botulinum toxin as an adjunct to motor learning therapy and surgery for obstetrical brachial plexus injury","volume":"48","author":"DeMatteo","year":"2006","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.ejpn.2008.10.006_bib6","article-title":"Obstetric brachial palsy. Role of botulinum toxin type A in early treatment","volume":"37","author":"Pascual-Pascual","year":"2006","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejpn.2008.10.006_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"Suppl. 4","key":"10.1016\/j.ejpn.2008.10.006_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long-term use","volume":"13","author":"Naumann","year":"2006","journal-title":"Eur J Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2008.10.006_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/PL00007816","article-title":"Pharmacology and immunology of botulinum toxin serotypes","volume":"248","author":"Aoki","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0041-0101(02)00086-7","article-title":"Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety","volume":"40","author":"Aoki","year":"2002","journal-title":"Toxicon"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2008.10.006_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","article-title":"Pharmacology of botulinum toxin: differences between type A preparations","volume":"13","author":"Rosales","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2310\/7010.2006.00041","article-title":"Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity","volume":"21","author":"Goldstein","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1017\/S0012162201211426","article-title":"Adverse events following repeated injections with botulinum toxin A in children with spasticity","volume":"43","author":"Mohamed","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1469-8749.2007.00818.x","article-title":"High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy","volume":"49","author":"Willis","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpn.2006.08.006","article-title":"European consensus Table 2006 on botulinum toxin for children with cerebral palsy","volume":"10","author":"Heinen","year":"2006","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib16","unstructured":"Management of spasticity with botulinum toxin type A (Botox). 2005 [cited 12\/05\/08]; 3.0 [Available from: http:\/\/www.mdvu.org\/classrooms\/cme\/CHEMD3\/PedSpastDosing.pdf]."},{"key":"10.1016\/j.ejpn.2008.10.006_bib17","series-title":"Controversies in cerebral palsy","first-page":"215","article-title":"Botulinum toxin in the prevention of dislocation of spastic hip in cerebral palsy","author":"Pascual-Pascual","year":"2006"},{"key":"10.1016\/j.ejpn.2008.10.006_bib18","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/mds.21097","article-title":"When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy","volume":"21","author":"Heinen","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ejpn.2008.10.006_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1017\/S0012162201000445","article-title":"Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity","volume":"43","author":"Bakheit","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib20","first-page":"303","article-title":"[Guidelines for the treatment of child spasticity using botulinum toxin]","volume":"44","author":"Pascual-Pascual","year":"2007","journal-title":"Rev Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib21","first-page":"1369","article-title":"[Botulinum toxin as a treatment for infantile cerebral palsy]","volume":"25","author":"Pascual-Pascual","year":"1997","journal-title":"Rev Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1469-8749.2007.00823.x","article-title":"Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy","volume":"49","author":"Lowe","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.33588\/rn.3701.2003221","article-title":"[Botulinum toxin Type A. Indications and results]","volume":"37","author":"Poo","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jnnp.67.1.90","article-title":"Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases","volume":"67","author":"Bhatia","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ejpn.2008.10.006_bib25","first-page":"444","article-title":"[Iatrogenic botulism: a complication to be taken into account in the treatment of child spasticity]","volume":"37","author":"Beseler-Soto","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0966-6362(99)00054-5","article-title":"Recommendations for the use of botulinum toxin type A in the management of cerebral palsy","volume":"11","author":"Graham","year":"2000","journal-title":"Gait Posture"},{"issue":"suppl","key":"10.1016\/j.ejpn.2008.10.006_bib27","first-page":"35","article-title":"Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy","volume":"109","author":"Christine","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2008.10.006_bib28","unstructured":"Palisano R, Rosenbaum P, Bartlett D, Livingston M. GMFCS\u2014revised 2007 (www.canchild.ca)."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379808001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379808001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T02:43:44Z","timestamp":1738723424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379808001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1090379808001918"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2008.10.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}